The prestigious TAGOOR Group was established in the year 2005. Over the years, the group has expanded and diversified into a variety of businesses, namely;
Led by a dynamic entrepreneur and leader, Dr. P V Subramanyam Raju, the group with an average tenure of 10 years has shown path-breaking success and growth since its inception.
The unprecedented growth in the less time span is mainly due to the management belief in the concept of “Backward Integration”. The group is always looks in to the roots of the business and focusses to absorb adequate knowledge and amalgamate the same to manufacture the basic materials on their own which always adds value to the business in terms of economy and standards.
Team work guided by ‘Empathy' and ‘Dynamism', that provide guidance for current behaviour and inspiration for future actions.
Address customer needs by supplying high-quality material.
Game-changing inventory of finished products being demand ready round the clock.
Owning the power to enable and help customers ensure that products are delivered when needed, where needed.
Offering Innovative Product supply at affordable prices.
Round the clock availability to the customers offering care, innovative solutions and help them succeed.
These priorities and principles make TAGOOR Group a supplier of choice both in the domestic as well as global markets.
The success of TAGOOR Group as a bulk drug intermediate manufacturer paved the way to upgrade its chemical entity. They have since built 2 state of the art facilities with upgraded and environmental friendly machinery at West Godavari district of Andhra Pradesh, India popularly called:
TAGOOR LABORATORIES PVT. LTD. & TAGOOR CHEMICALS PVT. LTD.
Both the facilities are of cGMP standards. The group has now progressed towards manufacturing Active Pharmaceutical Ingredients (APIs) in addition to their existing business of intermediates.
The combined facility is well established with 130 reactors ranging from 1 kl to 15 kl with a total capacity of 500 KL. The objective of the company is to produce APIs and key intermediates with world class quality at highly competitive prices. The company has highly strengthened Production, QC, QA and R&D team for the production of bulk drugs and their intermediates.
The industry is more focused towards the policy of “RRR” (refers Reduce, Reuse and Recycle) briefly Reducing the quantity of media and reagents used in the chemical transformations, Reusing and Recycling the solvents and other materials for the subsequent processes without affecting the quality of finished goods.
The greatest strength of the Tagoor API units is that they isolate valuable by-products which are generated during the process of making bulk drugs and intermediates in independently designed production blocks. The concept is economically attractive and environmentally friendly in the view of reducing the waste generation.
The company uses ground-breaking, pioneering equipment necessary for diverse chemical transformations such as:
